Scarica l'app Stockscreener
23.18
1.82%
-0.43
Dopo l'orario di chiusura:
23.28
0.10
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$23.61
Aprire:
$23.61
Volume 24 ore:
36.64M
Relative Volume:
0.74
Capitalizzazione di mercato:
$131.79B
Reddito:
$62.46B
Utile/perdita netta:
$7.88B
Rapporto P/E:
16.80
EPS:
1.38
Flusso di cassa netto:
$11.22B
1 W Prestazione:
+0.61%
1M Prestazione:
+0.56%
6M Prestazione:
-10.26%
1 anno Prestazione:
-18.09%
Intervallo 1D:
$23.11
$23.64
Intervallo di 1 settimana:
$22.81
$23.66
Portata 52W:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.18 | 130.99B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
719.39 | 670.62B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
152.43 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
183.09 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
111.87 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
68.60 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance
U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com
Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? - The Motley Fool
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha
US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com
Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks
US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com
Sleep Aids Market Generated Opportunities, Future Scope - openPR.com
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research CommunityMETRO - METRO - NEWS CHANNEL NEBRASKA
Specialty Injectable Generics Market Is Booming So Rapidly - openPR.com
Immunostimulant Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
Chlorphenamine Maleate API Market Trends, Demand, and Future Outlook | Pfizer Inc., Novartis AG, Sanofi S.A. - openPR.com
Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 26.50% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Investing In The Promising PD1/VEGF Bispecific; Pfizer And Instil Could Be Good Candidates - Seeking Alpha
Pfizer (PFE) Secures $1.25B Cancer Drug Licensing Deal - GuruFocus
25,379 Shares in Pfizer Inc. (NYSE:PFE) Bought by PVG Asset Management Corp - InsuranceNewsNet
Pfizer’s SWOT analysis: stock outlook amid strategic moves and pipeline potential - Investing.com India
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost - Yahoo Finance
Down 63%, Should You Buy the Dip on Pfizer? - AOL.com
Pfizer's 7.5% Dividend: Income Haven or House of Cards? - MSN
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success - simplywall.st
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug - Contract Pharma
FDA Advisory Panel Backs COVID Vaccine Update, Impacting Pfizer (PFE) - GuruFocus
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting - PR Newswire
Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Investing News Network
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Pfizer
Pfizer, Astellas Pharma's Prostate Cancer Treatment Shows 30% Reduction in Risk of Death - marketscreener.com
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Ove - GuruFocus
Was Jim Cramer Right About Pfizer Inc. (PFE)? - Yahoo Finance
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Yahoo Finance
COVID shots should target newer strains of JN.1 variant, US FDA advisers say - marketscreener.com
Pfizer Cements Win Axing Hemophilia Patents at Federal Circuit - Bloomberg Law News
Was Jim Cramer Right About These 12 Stocks? - Insider Monkey
Changes are happening around COVID-19 vaccines: Here's what to know - USA Today
Epirubicin Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Teva Pharmaceutical Industries Ltd. - openPR.com
Pfizer Jolted Higher On A Merck-Rivaling Deal. Is It A Buy? - Investor's Business Daily
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - KMVU FOX 26 Medford
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive
Vitiligo Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
US FDA advisers to weigh composition of COVID vaccines for 2025-2026 - marketscreener.com
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support - BioSpace
FDA Asks Pfizer/BioNTech, Moderna To Add Myocarditis Risk to COVID-19 Vaccines - BioSpace
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Prices for new US drugs doubled in 4 years as focus on rare disease grows - marketscreener.com
Pneumococcal Vaccines Market Insights and Forecast from 2025 - openPR.com
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):